EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Compass Therapeutics's Enterprise Value is $52.90 Mil.
Compass Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-40.62 Mil. Therefore, Compass Therapeutics's EV-to-FCF for today is -1.30.
The historical rank and industry rank for Compass Therapeutics's EV-to-FCF or its related term are showing as below:
CMPX'
s EV-to-FCF Range Over the Past 10 Years
Min: -15.04 Med: 0 Max: 0.65
Current: -1.3
During the past 6 years, the highest EV-to-FCF of Compass Therapeutics was 0.65. The lowest was -15.04. And the median was 0.00.
CMPX's EV-to-FCF is ranked worse than 100% of 392
companies
in the Biotechnology industry
Industry Median: 4.3
vs CMPX: -1.30
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Compass Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Compass Therapeutics's EV-to-FCF
For the Biotechnology subindustry, Compass Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Compass Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Compass Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Compass Therapeutics's EV-to-FCF falls into.
Compass Therapeutics's current Enterprise Value is $52.90 Mil.
Compass Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-40.62 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Compass Therapeutics's PE Ratio for today is calculated as:
Compass Therapeutics's share price for today is $1.45.
Compass Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.330.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Compass Therapeutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Compass Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Compass Therapeutics (Compass Therapeutics) Business Description
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. The company has drugged over 40 immune targets and generated a diverse pipeline of monoclonal and multispecific therapeutic candidates with potential to transform care for patients with cancer or autoimmune diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CMPX has been successfully added to your 